# Olaparib+Trastuzumab+Pertuzumab Neoadjuvant for Elderly HER2+ Breast Cancer

> **NCT07695259** · PHASE4 · RECRUITING · sponsor: **Wen-Ming Cao** · enrollment: 45 (estimated)

## Conditions studied

- Elderly Females
- HER2 + Breast Cancer
- Neoadjuvant Therapy

## Interventions

- **DRUG:** olaparib combined with trastuzumab and pertuzumab

## Key facts

- **NCT ID:** NCT07695259
- **Lead sponsor:** Wen-Ming Cao
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-05-25
- **Primary completion:** 2027-12-01
- **Final completion:** 2027-12-31
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2026-07-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07695259

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07695259, "Olaparib+Trastuzumab+Pertuzumab Neoadjuvant for Elderly HER2+ Breast Cancer". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07695259. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*